English | Español
English | Español
  • Insurance
  • Marketing
  • Pharmaceuticals
  • Technology/Innovation
  • Regulatory
  • Community

United States

+ Pharmaceuticals
Patient Daily | Nov 10, 2025

Political commentator on 340B abuse: 'They're lining pockets, not helping patients'

Trending

+ Pharmaceuticals
Patient Daily | Aug 6, 2026

FDA approves Replimune’s melanoma drug Tudriqev after advisory committee debate

+ Pharmaceuticals
Patient Daily | Aug 4, 2026

Merck reports mixed results for tulisokibart in recent clinical trials and financial update

+ Regulatory
M. Y. Bailey | Aug 7, 2026

PhRMA's Zirkelbach: 340B program has changed dramatically with 'little transparency into how patients benefit'

Patient Daily reports | Aug 10, 2026

SoCal Breathe Free warns persistent sinus symptoms may signal chronic inflammation



Community
Insurance
Marketing
Pharmaceuticals
Regulatory
Technology/Innovation
About
Contact
© 2026 Patient Daily